|
[1]CZAJA AJ.Rapidity of treatment response and outcome in type 1 autoimmune hepatitis[J].J Hepatol,2009,51(1):161-167.
|
|
[2]European Association for the Study of the Liver.EASL clinical practice guidelines:autoimmune hepatitis[J].J Hepatol,2015,63(4):971-1004.
|
|
[3]GRONBAEK L,VILSTRUP H,JEPSEN P.Autoimmune hepatitis in Denmark:incidence,prevalence,prognosis,and causes of death.A nationwide registry-based cohort study[J].J Hepatol,2014,60(3):612-617.
|
|
[4]de BOER YS,van GERVEN NM,ZWIERS A,et al.Genomewide association study identifies variants associated with autoimmune hepatitis type 1[J].Gastroenterology,2014,147(2):443-452.e5.
|
|
[5]FERRI S,LONGHI MS,de MOLO C,et al.A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis[J].Hepatology,2010,52(3):999-1007.
|
|
[6]YEOMAN AD,WESTBROOK RH,ZEN Y,et al.Prognosis of acute severe autoimmune hepatitis(AS-AIH):the role of corticosteroids in modifying outcome[J].J Hepatol,2014,61(4):876-882.
|
|
[7]KIRSTEIN MM,METZLER F,GEIGER E,et al.Prediction of short-and long-term outcome in patients with autoimmune hepatitis[J].Hepatology,2015,62(5):1524-1535.
|
|
[8]COUTO CA,BITTENCOURT PL,PIRTA G,et al.Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis[J].Hepatology,2014,59(2):592-600.
|
|
[9]de BOER YS,van NIEUWKERK CM,WITTE BI,et al.Assessment of the histopathological key features in autoimmune hepatitis[J].Histopathology,2015,66(3):351-362.
|
|
[10]QIU D,WANG Q,WANG H,et al.Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients[J].J Hepatol,2011,54(2):340-347.
|
|
[11]MANNS MP,LOHSE AW,VERGANI D.Autoimmune hepatitis——Update 2015[J].J Hepatol,2015,62(1 Suppl):s100-s111.
|
|
[12]MANNS MP,WOYNAROWSKI M,KREISEL W,et al.Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J].Gastroenterology,2010,139(4):1198-1206.
|
|
[13]ZACHOU K,GATSELIS N,PAPADAMOU G,et al.Mycophenolate for the treatment of autoimmune hepatitis:prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients[J].J Hepatol,2011,55(3):636-646.
|
|
[14]CZAJA AJ.Current and prospective pharmacotherapy for autoimmune hepatitis[J].Expert Opin Pharmacother,2014,15(12):1715-1736.
|
|
[15]KERKAR N,DUGAN C,RUMBO C,et al.Rapamycin successfully treats post-transplant autoimmune hepatitis[J].Am J Transplant,2005,5(5):1085-1089.
|
|
[16]BRUNS H,MEINKEN C,SCHAUENBERG P,et al.Anti-TNF immunotherapy reduces CD8+T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans[J].J Clin Invest,2009,119(5):1167-1177.
|
|
[17]SCHRAMM C,SCHNEIDER A,MARX A,et al.Adalimumab could suppress the activity of non alcoholic steatohepatitis(NASH)[J].Z Gastroenterol,2008,46(12):1369-1371.
|
|
[18]NAKAYAMA S.Autoimmune hepatitis triggered by anti-TNF-alpha therapy[J].Case Rep Med,2013,2013:561748.
|
|
[19]BOETTICHER NC,PEINE CJ,KWO P,et al.A randomized,double-blinded,placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis[J].Gastroenterology,2008,135(6):1953-1960.
|
|
[20]WEILER-NORMANN C,SCHRAMM C,QUAAS A,et al.Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis[J].J Hepatol,2013,58(3):529-534.
|
|
[21]CAREY EJ,SOMARATNE K,RAKELA J.Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome[J].Rev Med Chil,2011,139(11):1484-1487.
|
|
[22]BARTH E,CLAWSON J.A case of autoimmune hepatitis treated with rituximab[J].Case Rep Gastroenterol,2010,4(3):502-509.
|
|
[23]BURAK KW,SWAIN MG,SANTODOMINGO-GARZON T,et al.Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy[J].Can J Gastroenterol,2013,27(5):273-280.
|
|
[24]TAUBERT R,HARDTKE-WOLENSKI M,NOYAN F,et al.Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies[J].J Hepatol,2014,61(5):1106-1114.
|
|
[25]GRANT CR,LIBERAL R,HOLDER BS,et al.Dysfunctional CD39(POS)regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis[J].Hepatology,2014,59(3):1007-1015.
|
|
[26]HOLDER BS,GRANT CR,LIBERAL R,et al.Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2[J].J Autoimmun,2014,53:26-32.
|
|
[27]LAPIERRE P,BELAND K,YANG R,et al.Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance[J].Hepatology,2013,57(1):217-227.
|
|
[28]LONGHI MS,LIBERAL R,HOLDER B,et al.Inhibition of interleukin-17 promotes differentiation of CD25(-)cells into stable T regulatory cells in patients with autoimmune hepatitis[J].Gastroenterology,2012,142(7):1526-1535.e6.
|
|
[29]ZHANG H,LIU Y,BIAN Z,et al.The critical role of myeloidderived suppressor cells and FXR activation in immune-mediated liver injury[J].J Autoimmun,2014,53:55-66.
|
DownLoad: